Inside the research
Labcorp Holdings Inc.
LH Research profile · latest available data
Price overview
$309.64
▲ +0.69 (+0.2%)
| 52w hi | $338.61 |
|---|---|
| 52w lo | $244.17 |
| Vol | 821.50K |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.53
| Short | +0.42 |
|---|---|
| Medium | +0.65 |
| Long | +0.50 |
computed 2026-09-27
Key fundamentals
Labcorp Holdings Inc.
Healthcare · Diagnostics & Research
| Market cap | $25.11B |
|---|---|
| Enterprise value | $31.81B |
| Trailing P/E | 25.63x |
| Forward P/E | 15.60x |
| EV / EBITDA | 13.71x |
| P / S (ttm) | 1.75x |
| Profit margin | 7.0% |
| Return on equity | 11.7% |
| Revenue growth | +5.8% |
| Earnings growth | +28.2% |
| Debt / equity | 79.12 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.28 | |
| Sector | +0.08 | |
| Technical | +0.35 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics; a strategic alliance with the National Association of Community Health Centers to support current and emerging clinical leaders through the NACHC Leadership Exchange for Chief Medical Officers; and Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North Carolina.
Risk Metrics
| Beta vs SPX | 0.54 |
|---|---|
| Corr SPX | 0.37 |
| Annual vol | 23.5% |
| Annual ret | +19.3% |
| Sharpe | 0.82 |
| Max DD | -17.4% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $310.06 |
|---|---|
| High / Low | $340.00 / $270.00 |
| Median | $320.00 |
| Analysts | 17 |
| Strong Buy | 3 | |
|---|---|---|
| Buy | 12 | |
| Hold | 4 | |
| Sell | 0 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-04-08 | Evercore ISI Group | → Outperform |
| 2026-02-24 | Piper Sandler | → Neutral |
| 2026-02-18 | JP Morgan | → Overweight |
| 2026-02-18 | Baird | → Outperform |
| 2026-02-06 | JP Morgan | → Overweight |
| 2025-11-07 | JP Morgan | → Overweight |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-14 | Officer / Director Change | read |
| 2026-07-30 | Earnings Release, Exhibits | read |
| 2026-07-10 | Reg FD Disclosure, Exhibits | read |
| 2026-06-30 | Reg FD Disclosure, Exhibits | read |
| 2026-05-27 | Reg FD Disclosure, Exhibits | read |
| 2026-05-26 | Shareholder Vote | read |
| 2026-04-30 | Earnings Release, Exhibits | read |
| 2026-04-09 | Reg FD Disclosure, Exhibits | read |
| 2026-03-31 | Reg FD Disclosure, Exhibits | read |
| 2026-03-20 | Material Agreement, Material Obligation… | read |
| 2026-02-17 | Earnings Release, Exhibits | read |
| 2026-02-09 | Officer / Director Change, Reg FD Disclosure… | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-11 | Schechter Adam H | President & CEO | Sell | 4.67K | $1.50M |
| 2026-08-04 | Summy Amy B. | EVP, Chief Marketing Offi | Sell | 924 | $283.43K |
| 2026-08-03 | Wilkinson Peter J | SVP, Chief Accounting Off | Option exercise | 1.34K | $279.98K |
| 2026-08-03 | Wilkinson Peter J | SVP, Chief Accounting Off | Sell | 1.34K | $413.75K |
| 2026-08-03 | Wilkinson Peter J | SVP, Chief Accounting Off | Sell | 82 | $25.36K |
| 2026-07-02 | Vaughn Bryan T | EVP and President, Diagno | Sell | 234 | $66.97K |
| 2026-07-02 | Kyle Kathryn W | EVP, Chief Legal Officer | Sell | 92 | $26.33K |
| 2026-07-01 | Kyle Kathryn W | EVP, Chief Legal Officer | Withheld for tax | 73 | $20.72K |
| 2026-07-01 | Vaughn Bryan T | EVP and President, Diagno | Withheld for tax | 93 | $26.40K |
| 2026-07-01 | Vaughn Bryan T | EVP and President, Diagno | Option exercise | 327 | — |
Flow & Concentration
| Insider 180d net | -$4.02M |
|---|---|
| Insider buys / sells | 0 / 8 |
| Insider bias | Sellers |
| 13F holders | 8 |
| Top-5 share | 99.1% |
| HHI | 4,233 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $1.09B | 3.91M |
| Fidelity / FMR LLC | $533.36M | 1.90M |
| Capital Research / Capital World | $144.50M | 516.07K |
| Millennium Management | $67.21M | 240.04K |
| Citadel Advisors | $30.43M | 108.67K |
| AQR Capital Management | $16.93M | 61.00K |
| Bridgewater Associates | $783.44K | 2.80K |
| T. Rowe Price Group | $33.56K | 119.84K |
As of 2026-06-30
Dividends
| Yield (TTM) | 0.47% |
|---|---|
| $ / share (TTM) | $1.44 |
| 5y CAGR | — |
Annual dividend per share
| 1994 | $0.17 |
|---|---|
| 2022 | $1.86 |
| 2023 | $2.68 |
| 2024 | $2.88 |
| 2025 | $2.88 |
| 2026 | $0.72 |
SEC Filings
The Long Run
FY 2009–2025 · 15 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $13.95B | +9.2% | |
| Gross profit | $3.36B | +3.9% | |
| Operating income | $725.60M | -1.1% | |
| Net income | $418.00M | -1.9% | |
| Cash from ops | $1.64B | +4.7% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $308.24 | $312.30 | $306.55 | $309.64 | 821.50K |
| Sep 24 | $304.62 | $309.54 | $303.13 | $308.95 | 784.90K |
| Sep 23 | $311.91 | $312.82 | $303.50 | $303.98 | 909.20K |
| Sep 22 | $303.46 | $316.53 | $303.46 | $311.54 | 1.91M |
| Sep 21 | $321.95 | $323.84 | $318.94 | $320.99 | 487.40K |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →